Epicentrx To Present Positive Phase 2A Clinical Data With Its Adapt-001 TGF-Β Trap Program In Checkpoint Inhibitor Resistant Patients At The 2024 AACR Meeting

  • Christopher Larson

Press/Media

Period2 Apr 2024

Media coverage

97

Media coverage